首页> 外国专利> THE USE OF DEFERIPRONE AND METHODS TO TREAT AND/OR PREVENT FRIEDREICH ATAXIA RESULTING FROM INTRACELLULAR MISHANDLING OF IRON

THE USE OF DEFERIPRONE AND METHODS TO TREAT AND/OR PREVENT FRIEDREICH ATAXIA RESULTING FROM INTRACELLULAR MISHANDLING OF IRON

机译:去铁酮的使用和方法治疗和/或预防铁鞘内充填导致的弗里德里希·阿塔克氏菌

摘要

A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.
机译:用于预防,稳定,治疗或逆转由线粒体铁诱导的损伤导致的铁诱导的FRDA疾病的治疗有效量的去铁酮或其衍生物或其生理上可接受的盐,可优先减少线粒体中的铁。还用于治疗其他影响大脑的疾病,其中导致最终病理的关键因素是铁的细胞内处理不当。

著录项

  • 公开/公告号PL1991225T3

    专利类型

  • 公开/公告日2014-04-30

    原文格式PDF

  • 申请/专利权人 APOTEX TECHNOLOGIES INC.;

    申请/专利号PL20070701800T

  • 申请日2007-02-21

  • 分类号A61K31/195;A61K31/4196;A61K31/4412;

  • 国家 PL

  • 入库时间 2022-08-21 15:56:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号